Cdh5(PAC)-CreERT2 Mouse

Random Transgenic

Cdh5(PAC)-CreERT2 Random Transgenic Mouse Model

C57BL/6 Background

  • Model #
  • Genotype
  • Nomenclature
  • 13073-F
  • 13073-M
  • An inducible cre deleter under the control of the vascular endothelial cadherin (Cdh5(PAC)) promoter
  • Cre recombination is inducible via administration of tamoxifen
  • Useful for study of angiogenesis, atherosclerosis and neovascularization
  • Non-induced Cdh5(PAC)-CreERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Cdh5(PAC)-CreERT2 mice demonstrate high levels of recombinase-mediated gene deletion in vascular endothelial cells (95%+).
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.


The Cdh5(PAC)-CreERT2 Mouse was developed in the laboratory of Ralf Adams at the London Research Institute. The model was generated by microinjecting a transgene containing a genomic Cdh5(PAC) promoter fragment fused to a CreERT2 cDNA into C57BL/6 zygotes. Founder lines were backcrossed to C57BL/6 for at least five generations. Taconic received embryos from CRT in 2013.


Sponsor: Cancer Research Technology


Limited quantities of breeders are available for purchase after execution of a license.

Ordering Note: Animals ordered at 4 weeks of age require rapid genotyping and a $40.00 per mouse charge will be added.





Initial Publication:

Sörensen I, Adams RH, Gossler A. (2009) DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. Blood. 113(22):5680-8.

Access to this model requires execution of a Limited Breeding Agreement. The current agreement fees are:
  • $3,000/€2550 per year for non-profit users
  • $10,000/€8500 per year for for-profit users
Once the agreement is executed, you may order mice for use in breeding and crossbreeding. Please contact Taconic Customer Service for details.

Welcome! Tell us a little about yourself